25000 Participants Needed

Genomic Profiling for Cancer

(ASAP Trial)

Recruiting at 1 trial location
CW
ML
RE
Overseen ByRachel Elsey, PharmD
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Avera McKennan Hospital & University Health Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to explore the genetic makeup of individuals with pre-cancerous conditions or cancer to understand the drivers of these diseases. By analyzing participants' DNA and proteins, the researchers hope to discover new markers that could aid in diagnosing and treating various cancers. Participants should have a pre-cancerous condition or a cancer diagnosis and be involved in medical evaluation or follow-up. Joining this study might not only assist with personal treatment options but also advance cancer research for future patients. As an unphased trial, this study offers participants the opportunity to contribute to groundbreaking research that could lead to significant advancements in cancer diagnosis and treatment.

Why are researchers excited about this trial?

Researchers are excited about the Avera Cancer Sequencing and Analytics Protocol (ASAP) because it represents a cutting-edge approach to understanding cancer on a genetic level. Unlike traditional treatments that target the tumor as a whole, this protocol uses advanced sequencing technology to analyze the unique genetic makeup of individual cancers. By doing so, it aims to identify specific genetic mutations that can be targeted with precision therapies. This personalized approach could lead to more effective and tailored treatments, potentially improving outcomes and reducing side effects for cancer patients.

Who Is on the Research Team?

RE

Rachel Elsey, PharmD

Principal Investigator

Avera Cancer Institute

Are You a Good Fit for This Trial?

Inclusion Criteria

Must be undergoing a workup or being followed for a premalignant condition or have a diagnosis of cancer
Must voluntarily sign and understand the most current IRB-approved consent form prior to study participation

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Molecular Profiling

Comprehensive molecular profiling including somatic tumor testing, whole exome sequencing, whole transcriptome sequencing, proteomics, and selected instances of whole genome sequencing

8-12 weeks

Hereditary Cancer Testing

Broad hereditary cancer testing with implications in screening, prognosis, and therapeutics

4-6 weeks

Follow-up

Participants are monitored for safety and effectiveness after testing, with electronic health records abstracted, curated, annotated, and linked to genomic information

Long-term

Biobanking

Participants may consent to have their samples stored in a biobank for future research

What Are the Treatments Tested in This Trial?

Find a Clinic Near You

Who Is Running the Clinical Trial?

Avera McKennan Hospital & University Health Center

Lead Sponsor

Trials
35
Recruited
29,200+

Sema4

Collaborator

Trials
2
Recruited
25,700+